Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company

Merck Boosts Global Distribution Capabilities with €180 Million Expansion of German Center

Fineline Cube Jun 11, 2024

Merck KGaA (ETR: MRK), the German life science and technology company, announced last week a...

Company Drug

Gilead’s Bulevirtide-PegIFN Combo Achieves High HDV Remission Rates in Phase IIb Trial

Fineline Cube Jun 11, 2024

Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company at the forefront of HIV and liver...

Company Drug

AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC

Fineline Cube Jun 11, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...

Company Deals

MSD Makes Undisclosed Equity Investment in Cancer Diagnostics Firm DELFI Diagnostics

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an equity investment into DELFI Diagnostics,...

Company Deals

GSK Finalizes Acquisition of Oligonucleotide Specialist Elsie Biotechnologies for Up to $50 Million

Fineline Cube Jun 7, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has announced the completion of the...

Policy / Regulatory

Four More Chinese Provinces Include ART in Medical Insurance Payment System

Fineline Cube Jun 7, 2024

The provincial governments of Jiangxi, Shanghai, Qinghai, and Zhejiang have added assisted reproductive technology (ART)...

Company Legal / IP

J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million

Fineline Cube Jun 7, 2024

Johnson & Johnson (J&J; NYSE: JNJ) suffered a defeat in a US court this week,...

Company

MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President

Fineline Cube Jun 7, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as...

Policy / Regulatory

China Unveils Ambitious 2024 Medical Reforms with Increased Investment and Policy Reforms

Fineline Cube Jun 7, 2024

The State Council has issued a notification outlining key medical system reforms for 2024, aiming...

Company

Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration

Fineline Cube Jun 7, 2024

Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set...

Company Medical Device

Sansure Biotech’s HBV RNA Detection Kit Receives NMPA Marketing Approval

Fineline Cube Jun 7, 2024

Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced...

Company Medical Device

MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter

Fineline Cube Jun 7, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Drug

Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment

Fineline Cube Jun 7, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...

Company Drug

Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis

Fineline Cube Jun 7, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan

Fineline Cube Jun 7, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Drug

HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies

Fineline Cube Jun 7, 2024

HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...

Company Deals

Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization

Fineline Cube Jun 6, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...

Company Drug

Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting

Fineline Cube Jun 6, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...

Company Drug

Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China

Fineline Cube Jun 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary

Fineline Cube Jun 6, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed...

Posts pagination

1 … 344 345 346 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.